Sonnet BioTherapeutics Holdings Inc Ordinary Shares H3D
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://www.sonnetbio.com
Valuation
|
Metric
|
H3D
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.00 |
Price/Sales | 21.22 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
H3D
|
|---|---|
Quick Ratio | 1.21 |
Current Ratio | 1.74 |
Interest Coverage | — |
Quick Ratio
H3D
Profitability
|
Metric
|
H3D
|
|---|---|
Return on Assets (Normalized) | −182.46% |
Return on Equity (Normalized) | −938.08% |
Return on Invested Capital (Normalized) | −820.59% |
Return on Assets
H3D
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Khfvfjcnf | Fzf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vrnzchmh | Bghhbyf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wmkfghd | Kdytymc | $97.8 Bil | |
MRNA
| Moderna Inc | Flkgjfcpg | Xrpj | $38.8 Bil | |
ARGX
| argenx SE ADR | Hcjpvytby | Bkg | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Kdbnybk | Tpqg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dljxghsv | Zqdybgx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mfwqxnvw | Tgmjxr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hyvnqfrx | Hgcskzy | $12.5 Bil | |
INCY
| Incyte Corp | Stdbvvw | Hqsrnj | $11.5 Bil |